Analysts think LXEO stock price could increase by 18%
Jun 14, 2024, 6:32 AM
-21.34%
What does LXEO do
Lexeo Therapeutics Inc., a clinical-stage genetic medicine company headquartered in New York City, went public on 2023-11-03 and focuses on developing gene therapies for severe cardiovascular diseases with no current genetic treatments. The company's key projects include LX2006 for Friedreich’s ataxia cardiomyopathy, and other candidates targeting various genetic cardiac disorders.
8 analysts think LXEO stock price will increase by 17.71%. The current median analyst target is $21.93 compared to a current stock price of $18.63. The lowest analysts target is $19.19 and the highest analyst target is $25.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
